ABRILADA

Pfizer Laboratories Div Pfizer Inc🇺🇸 United States

FDA Page

Effective Date: Dec 22, 2025
Approval ID: 81a33cfa-262f-4432-a05d-7dd260928437
Products: 5 registered
Version: 7

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA. ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019 ABRILADA (adalimumab-afzb) is biosimilar to HUMIRA (adalimumab).

Quick Stats

Total Products5

Labelers2

Label Sections53

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.